ETR:SBS

Stratec Stock Forecast, Price & News

€111.80

+1.40 (+1.27 %)

(As of 05/17/2021 12:00 AM ET)

Add

Compare

Today's Range

€109.80

▼

€112.40

50-Day Range

€107.00

▼

€118.80

52-Week Range

€74.50

▼

€145.00

Volume7,758 shs

Average Volume6,253 shs

Market Capitalization$1.35 billion

P/E Ratio39.58

Dividend Yield0.82%

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive SBS News and Ratings via Email

Sign-up to receive the latest news and ratings for Stratec and its competitors with MarketBeat's FREE daily newsletter.

About Stratec

Stratec SE designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany and internationally. It operates through three segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment designs and manufactures automated analyzer systems, including service parts and consumables for clinical diagnostics and biotechnology customers. The Diatron segment offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications. The Smart Consumables segment develops and manufactures smart consumables in the fields of diagnostics, life sciences, and medical technologies. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.

Stratec (ETR:SBS) Given a €151.00 Price Target at Deutsche Bank Aktiengesellschaft
May 10, 2021 | americanbankingnews.com

Stratec (ETR:SBS) PT Set at €112.00 by Warburg Research
May 7, 2021 | americanbankingnews.com

Stratec (ETR:SBS) Given a €129.00 Price Target at Kepler Capital Markets
April 27, 2021 | americanbankingnews.com

Stratec (ETR:SBS) PT Set at €151.00 by Deutsche Bank Aktiengesellschaft
April 27, 2021 | americanbankingnews.com

Stratec (ETR:SBS) PT Set at €130.00 by Berenberg Bank
April 27, 2021 | americanbankingnews.com

Stratec SE (FRA:SBS) Has A ROE Of 10%
January 21, 2019 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange ETR

Industry Medical Devices

Sub-IndustryN/A

SectorMedical

Current SymbolETR:SBS

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.stratec.com

Phone+49-7082-79160

Employees1,223

Year FoundedN/A

Sales & Book Value

Annual Sales$265.59 million

Price / Sales5.09

Cash Flow€3.93 per share

Price / Cash Flow28.42

Book Value€15.11 per share

Price / Book7.40

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Debt

Debt-to-Equity Ratio57.15

Current Ratio3.88

Quick Ratio2.28

Price-To-Earnings

Trailing P/E Ratio39.58

Forward P/E RatioN/A

P/E GrowthN/A

Miscellaneous

Outstanding Shares12,099,400

Market Cap$1.35 billion

Next Earnings Date8/6/2021 (Estimated)

OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.30 out of 5 stars

2.3 Analyst's Opinion

Consensus Rating
Stratec has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of €130.50, Stratec has a forecasted upside of 16.7% from its current price of €111.80.
Amount of Analyst Coverage
Stratec has only been the subject of 4 research reports in the past 90 days.

2.8 Community Rank

Outperform Votes
Stratec has received 156 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Stratec has received 120 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Stratec has received 56.52% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Stratec and other stocks. Vote “Outperform” if you believe SBS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SBS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.8 Dividend Strength

Dividend Yield
Stratec has a dividend yield of 0.82%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Stratec does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Stratec is 31.86%. This payout ratio is at a healthy, sustainable level, below 75%.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Stratec insiders have not sold or bought any company stock.

0.6 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Stratec is 39.58, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.55.
Price to Earnings Ratio vs. Sector
The P/E ratio of Stratec is 39.58, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 41.85.
Price to Book Value per Share Ratio
Stratec has a P/B Ratio of 7.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Stratec (ETR:SBS) Frequently Asked Questions

Is Stratec a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stratec in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Stratec stock.
View analyst ratings for Stratec or view top-rated stocks.

What stocks does MarketBeat like better than Stratec?

Wall Street analysts have given Stratec a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Stratec wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Stratec's next earnings date?

Stratec is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021.
View our earnings forecast for Stratec.

How has Stratec's stock price been impacted by Coronavirus (COVID-19)?

Stratec's stock was trading at €64.00 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SBS shares have increased by 74.7% and is now trading at €111.80.
View which stocks have been most impacted by COVID-19.

Is Stratec a good dividend stock?

Stratec pays an annual dividend of €0.90 per share and currently has a dividend yield of 0.82%. The dividend payout ratio of Stratec is 31.86%. This payout ratio is at a healthy, sustainable level, below 75%.
View Stratec's dividend history.

What price target have analysts set for SBS?

4 analysts have issued 12 month target prices for Stratec's stock. Their forecasts range from €112.00 to €151.00. On average, they expect Stratec's stock price to reach €130.50 in the next twelve months. This suggests a possible upside of 16.7% from the stock's current price.
View analysts' price targets for Stratec or view top-rated stocks among Wall Street analysts.

Who are Stratec's key executives?

Stratec's management team includes the following people:

Mr. Marcus Wolfinger, Chairman of Board of Management & CEO (Age 54, Pay $707k)
Dr. Robert Siegle, Director of Fin. & HR and Member of Board of Management (Age 54, Pay $566k)
Dr. Claus Vielsack, Director of Product Devel. & Member of Board of Management (Age 54, Pay $484k)
Mr. Hermann Leistner, Founder & Advisor (Age 75)
Mr. Jan Keppeler, Head of Investor Relations & Corp. Communications
Mr. Andre Loy, Director of Corp. Communications
Mr. Roland Utz, Head of Supply Chain Management & Sr. VP

Who are some of Stratec's key competitors?

Some companies that are related to Stratec include ConvaTec Group (CTEC), Butterfly Network (BFLY), Treace Medical Concepts (TMCI), 908 Devices (MASS), Avacta Group (AVCT), Drägerwerk AG & Co. KGaA (DRW3), NeuroPace (NPCE), Asensus Surgical (ASXC), Viemed Healthcare (VMD), Itamar Medical (ITMR), Viemed Healthcare (VMD), Creo Medical (CREO), Talis Biomedical (TLIS), Titan Medical (TMD) and Medica Group (MGP).
View all of SBS's competitors.

What other stocks do shareholders of Stratec own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stratec investors own include Great Portland Estates (GPOR), Gogo (GOGO), Depomed (DEPO), Cenovus Energy (CVE), 186808 (CHC), Bio-Rad Laboratories (BIO), Berkshire Hills Bancorp (BHLB), ASGN (ASGN), Apptio (APTI) and Anadarko Petroleum (APC).

What is Stratec's stock symbol?

Stratec trades on the ETR under the ticker symbol "SBS."

What is Stratec's stock price today?

One share of SBS stock can currently be purchased for approximately €111.80.

How much money does Stratec make?

Stratec has a market capitalization of $1.35 billion and generates $265.59 million in revenue each year.

How many employees does Stratec have?

Stratec employs 1,223 workers across the globe.

What is Stratec's official website?

The official website for Stratec is www.stratec.com.

Where are Stratec's headquarters?

Stratec is headquartered at Gewerbestr. 37, BIRKENFELD, 75217, Germany.

How can I contact Stratec?

Stratec's mailing address is Gewerbestr. 37, BIRKENFELD, 75217, Germany. The company can be reached via phone at +49-7082-79160.

This page was last updated on 5/18/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here